Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. (Nasdaq: ALLR) on October 27, 2023. The company is a Delaware corporation headquartered in Boston, MA, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory listing event rather than financial performance data.
Material Changes
The primary material event is the notification from Nasdaq Listing Qualifications staff that the company's Common Stock bid price closed below $1.00 per share for 30 consecutive business days, violating Listing Rule 5550(a)(2). Due to prior reverse stock splits (1:35 on March 24, 2023, and 1:40 on June 28, 2023) with a cumulative ratio exceeding 250:1, the company is ineligible for the standard 180-day compliance period.
Outlook, Risks, and Management Commentary
As a result of the violation, the company's Common Stock is scheduled for delisting from The Nasdaq Capital Market. Unless an appeal is requested, trading will be suspended on November 7, 2023, and a Form 25-NSE will be filed to remove the stock from listing. Management intends to request an appeal of the delisting determination. During the appeal process, the stock will continue to trade on Nasdaq.
Key Facts for Investor Verification
- Stock price has remained below $1.00 for 30 consecutive business days.
- Company is ineligible for a 180-day cure period due to cumulative reverse stock splits exceeding 250:1 in the last two years.
- Trading suspension is scheduled for November 7, 2023, pending the outcome of an intended appeal.
- Form 25-NSE will be filed to effectuate delisting if the appeal is not successful or if trading is suspended.